Pediatric rheumatology for the adult rheumatologist II: Uveitis in juvenile idiopathic arthritis

Tracey Wright, Randy Q. Cron

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Uveitis is an important and frequent extra-articular manifestation of juvenile idiopathic arthritis (JIA) that may result in poor visual outcome. Without early detection and aggressive therapy, the uveitis and topical steroid therapy used to treat it may result in cataracts, glaucoma, and even blindness. Fortunately, a variety of systemically administered anti-inflammatory agents have been found useful for the treatment of JIA associated uveitis. Methotrexate is often the first line disease modifying systemic agent used to help wean topical corticosteroids, but when this is not sufficiently effective there are a variety of other systemic medicines available. In particular, one of the tumor necrosis factor-α inhibitors, infliximab, has shown some promising results in difficult to treat JIA associated uveitis. With early screening and detection combined with aggressive therapy in difficult to treat cases, the morbidity associated with uveitis as part of JIA is on the decline.

Original languageEnglish (US)
Pages (from-to)205-210
Number of pages6
JournalJournal of Clinical Rheumatology
Issue number4
StatePublished - Aug 2007

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Pediatric rheumatology for the adult rheumatologist II: Uveitis in juvenile idiopathic arthritis'. Together they form a unique fingerprint.

Cite this